Vanda Pharmaceuticals price target raised to $20 from $18 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $18 and keeps a Buy rating on the shares. The firm added imsidolimab to its valuation assessment. Vanda’s “ambitious” long-term revenue goals look achievable, even without some late-stage assets, the analyst tells investors in a research note.